AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause
Alvopetro Announces 2025 Year End Reserves Including a 79% Increase in 1P Reserves, 2P Production Replacement Ratio of 530% and 2026 Capital Plan
